1 A-IIIC) met the eligibility criteria for the
primary objective analysis, with an additional 22 patien
2 The
primary objective and safety were assessed in the intent
3 In rural Senegal, we assessed the total (
primary objective)
and indirect effectiveness of a triva
4 The
primary objective,
by intention to treat, determined if
5 primary endpoint was broken up into three co-
primary objectives:
disease-free survival in the overall
6 This study's
primary objective examined the relationship between GSK2
7 treatments for depression is a long-standing
primary objective in both psychiatry and translational n
8 ic variation that increases crop yields is a
primary objective in plant breeding.
9 Our
primary objective in this exploratory study was to ident
10 The
primary objective in this phase 1 multicenter, investiga
11 control over crystal structure is one of the
primary objectives in crystal growth, the present lack o
12 Our
primary objectives in this study were to evaluate whethe
13 The
primary objective included analysis of geometric mean ti
14 coronary heart disease (CHD) patients, whose
primary objective is to compare the effect of 2 healthy
15 The
primary objective is to describe the relationship betwee
16 The
primary objective is to determine in the PARTNER 2 trial
17 The
primary objective is to identify biomarkers of severe RS
18 The
primary objective is to investigate the safety and toler
19 0.65, 95% CI 0.49-0.86; one-sided p=0.0012 [
primary objective met]).
20 ynthesis of each study's data, recording its
primary objective,
methodology, and results.
21 noted with eltrombopag and the trial met the
primary objective of a reduction in CRTEs; eltrombopag m
22 The
primary objective of acoustic metamaterial research is t
23 Although the presumption is often that the
primary objective of asking for family consent is to sec
24 ntaining optimal symptom control remains the
primary objective of asthma treatment.
25 Because a
primary objective of chemistry is to provide molecular-l
26 particles, understanding that structure is a
primary objective of condensed matter research.
27 The study did not meet its
primary objective of demonstrating that fludrocortisone
28 h persistent asthma in 35 countries with the
primary objective of evaluating whether mometasone furoa
29 ential soils collected in the AHHS, with the
primary objective of gaining a better understanding of d
30 The
primary objective of noninferiority at week 48 was met.
31 to-treat (m-MITT) population, ZTI-01 met the
primary objective of noninferiority compared with PIP-TA
32 The
primary objective of noninferiority of the humoral immun
33 The
primary objective of noninferiority was met: 7 patients
34 The
primary objective of our study was therefore to evaluate
35 The
primary objective of our study was to derive and evaluat
36 The
primary objective of part A (dose escalation) was to ass
37 The
primary objective of phase Ib was to determine the maxim
38 Although the
primary objective of reducing the proportion of subjects
39 ERPRETATION: The GOLD study did not meet its
primary objective of showing a significant improvement i
40 Designing tight-binding ligands is a
primary objective of small-molecule drug discovery.
41 The
primary objective of such a device is to see if addition
42 3%, 95% confidence interval 76%-91%) met the
primary objective of superiority versus the historical c
43 One
primary objective of synthetic biology is to improve the
44 The
primary objective of the analysis was to determine progr
45 The
primary objective of the AUC is to provide a framework f
46 A
primary objective of the Children's Oncology Group (COG)
47 The
primary objective of the decision process is to identify
48 A
primary objective of the European Academy for Allergy an
49 The
primary objective of the INFORM trial was to assess all-
50 The
primary objective of the KEYNOTE-001 trial was to assess
51 The
primary objective of the open-label extension study was
52 The
primary objective of the part B expansion phase was to e
53 The
primary objective of the present study was to determine
54 The
primary objective of the present study was to determine
55 The
primary objective of the present study was to evaluate e
56 The
primary objective of the study was safety and tolerabili
57 The
primary objective of the study was to assess the safety
58 The
primary objective of the study was to calculate prevalen
59 The
primary objective of the study was to compare progressio
60 The
primary objective of the study was to determine whether
61 The
primary objective of the study was to estimate the incid
62 sound for dengue fever screening; hence, the
primary objective of the study was to evaluate the utili
63 The
primary objective of the study was to explore the change
64 The
primary objective of the TAVR-LM registry is to evaluate
65 ons to this nested cohort study are that the
primary objective of the trial was designed to measure e
66 The
primary objective of the trial was event-free survival (
67 The
primary objective of these two trials was to determine t
68 A
primary objective of this article was to provide a gener
69 An important
primary objective of this council is to define the essen
70 The
primary objective of this international, multicenter, mu
71 The
primary objective of this pilot study was to test the fe
72 The
primary objective of this project was to decrease comput
73 The
primary objective of this randomized trial was to compar
74 The
primary objective of this retrospective analysis was to
75 Primary objective of this review was to measure complian
76 Therefore, the
primary objective of this scientific statement is to rev
77 The
primary objective of this study is to build and validate
78 The
primary objective of this study is to determine at what
79 The
primary objective of this study is to dimensionally and
80 The
primary objective of this study is to histologically eva
81 Primary objective of this study was the comparison of so
82 The
primary objective of this study was to assess the change
83 The
primary objective of this study was to assess whether th
84 The
primary objective of this study was to compare antibody
85 The
primary objective of this study was to describe and asse
86 The
primary objective of this study was to describe trends i
87 Primary objective of this study was to determine whether
88 The
primary objective of this study was to establish endotyp
89 The
primary objective of this study was to evaluate a range
90 The
primary objective of this study was to evaluate the asso
91 The
primary objective of this study was to evaluate the asso
92 The
primary objective of this study was to evaluate the caus
93 The
primary objective of this study was to evaluate the phys
94 The
primary objective of this study was to evaluate the safe
95 The
primary objective of this study was to evaluate the util
96 The
primary objective of this study was to examine the impac
97 The
primary objective of this study was to histologically co
98 The
primary objective of this study was to investigate five
99 The
primary objective of this study was to investigate the a
100 The
primary objective of this study was to obtain insights i
101 The
primary objective of this study was to provide a detaile
102 The
primary objective of this study was to show superiority
103 for a correction of overlapping peaks is the
primary objective of this study.
104 The
primary objective of this systematic review and meta-ana
105 The
primary objective of this systematic review was to evalu
106 The
primary objective of this three-arm cohort study was to
107 The
primary objective of this trial was to determine the saf
108 The
primary objective of this trial was to evaluate safety o
109 ociated independent monitoring strategy, the
primary objective of which was verification that tOPV wa
110 The
primary objectives of the exposure assessment are to est
111 The
primary objectives of the study were safety and tolerabi
112 The co-
primary objectives of the study were the evaluation of s
113 The
primary objectives of the study were to assess safety an
114 The
primary objectives of this analysis were to determine th
115 The
primary objectives of this extension study were to asses
116 The original planned
primary objectives of this phase 2 clinical trial were t
117 The
primary objectives of this study were to (1) evaluate wh
118 The
primary objectives of this study were to compare rates o
119 The
primary objectives of this study were to describe the fr
120 The
primary objectives of this study were to investigate cha
121 The
primary objectives of this study were to: a) assess whet
122 The
primary objectives of this trial were to determine safet
123 eport the prespecified final analysis of the
primary objectives,
OS and adverse events.
124 but if particulate matter reductions are the
primary objective,
other approaches to time-differentiat
125 The model's discrimination for the
primary objective performed better than the European Gro
126 End points included safety (
primary), objective response rate, and overall survival
127 tional longitudinal studies, having as their
primary objective the creation of postnatal growth chart
128 For the
primary objective,
the gingival thickness that best corr
129 Bangladesh, were enrolled in a study with a
primary objective to establish noninferiority of concomi
130 The
primary objective (
to determine the maximum tolerated do
131 The
primary objective was 1-year event-free survival (EFS) a
132 The part 2
primary objective was assessed by a composite primary en
133 The
primary objective was assessment of neutralising geometr
134 Primary objective was assessment of patient discomfort i
135 The
primary objective was estimating the maximum tolerated d
136 The
primary objective was feasibility, defined as the propor
137 The
primary objective was identifying the number of patients
138 The
primary objective was met in both treatment arms.
139 The
primary objective was met in six of the nine patients at
140 erform our planned statistical analysis, the
primary objective was modified to evaluate engraftment,
141 The
primary objective was mortality after subarachnoid hemor
142 Although the
primary objective was not met, subgroup analyses showed
143 he preplanned phase II cohort expansion, the
primary objective was objective response rate at week 24
144 The
primary objective was prediction of overall mortality (O
145 The
primary objective was product-related AEs.
146 The
primary objective was progression-free survival (PFS); s
147 The
primary objective was progression-free survival in the i
148 The
primary objective was recurrence-free survival (RFS), an
149 The
primary objective was safety (incidence of adverse event
150 The
primary objective was safety and immunogenicity of the Z
151 The
primary objective was safety and tolerability 28 days po
152 The
primary objective was safety and tolerability of RG-101.
153 The
primary objective was safety and tolerability, with seve
154 The
primary objective was safety evaluation.
155 The
primary objective was safety, including antibody testing
156 The
primary objective was the major molecular response (MMol
157 The
primary objective was the proportion of patients achievi
158 The
primary objective was the rate of partial hematologic re
159 The
primary objective was the vaccine effectiveness of at le
160 The
primary objective was to assess associations between ann
161 The
primary objective was to assess for improved progression
162 Our
primary objective was to assess protective efficacy agai
163 The
primary objective was to assess safety and feasibility o
164 The
primary objective was to assess safety and tolerability
165 The
primary objective was to assess safety and tolerability
166 The
primary objective was to assess safety and tolerability.
167 The
primary objective was to assess safety, tolerability, an
168 The
primary objective was to assess safety; secondary object
169 The
primary objective was to assess the diagnostic accuracy
170 The
primary objective was to assess the direct cost to Europ
171 The
primary objective was to assess the efficacy of the vacc
172 rial commenced with an internal pilot, whose
primary objective was to assess the feasibility of multi
173 The
primary objective was to assess the optimal dose schedul
174 The
primary objective was to assess the proportion of patien
175 The
primary objective was to assess the safety and tolerabil
176 The
primary objective was to assess the safety and tolerabil
177 The
primary objective was to assess the safety and tolerabil
178 The
primary objective was to assess the safety and tolerabil
179 The
primary objective was to assess the superiority of bOPV-
180 ntify and model prosocial vaccination as its
primary objective was to avert transmission.
181 Our
primary objective was to characterise product safety, an
182 The
primary objective was to compare average change in HbA(1
183 The
primary objective was to compare complete response (CR)
184 The
primary objective was to compare disease-free survival (
185 The
primary objective was to compare disease-free survival b
186 The
primary objective was to compare major adverse cardiovas
187 The
primary objective was to compare overall survival (OS) i
188 The
primary objective was to compare pimodivir pharmacokinet
189 The
primary objective was to compare targeted and standard b
190 The
primary objective was to compare the number of patients
191 The
primary objective was to compare the tracheal sealing pe
192 The
primary objective was to demonstrate improvement in prog
193 The
primary objective was to demonstrate noninferiority (10%
194 Primary objective was to demonstrate noninferiority of d
195 The
primary objective was to demonstrate statistical noninfe
196 The
primary objective was to demonstrate the clinical applic
197 The
primary objective was to demonstrate the superiority of
198 The
primary objective was to describe the OCT features at th
199 The
primary objective was to determine a recommended phase 2
200 The
primary objective was to determine GED-0301's effect on
201 Our
primary objective was to determine if baseline microbiot
202 The
primary objective was to determine if dietary nervonic a
203 The
primary objective was to determine safety, toxicity, and
204 Purpose
Primary objective was to determine the 10-year oncologic
205 The
primary objective was to determine the diagnostic perfor
206 The
primary objective was to determine the difference in NK
207 Our
primary objective was to determine the dose-response rel
208 In this study, our
primary objective was to determine the effect of timing
209 Our
primary objective was to determine the effect on risk of
210 tients received 28-day treatment cycles; the
primary objective was to determine the maximum tolerated
211 The
primary objective was to determine the maximum tolerated
212 The
primary objective was to determine the maximum tolerated
213 The phase 1
primary objective was to determine the maximum tolerated
214 The
primary objective was to determine the maximum tolerated
215 The
primary objective was to determine the overall response
216 The
primary objective was to determine the prevalence of ast
217 The
primary objective was to determine the prognostic impact
218 The
primary objective was to determine the progression-free
219 The
primary objective was to determine the proportion of pat
220 The
primary objective was to determine the risk of poor outc
221 The
primary objective was to determine the safety and recomm
222 The
primary objective was to determine the safety of the vac
223 Our
primary objective was to determine whether adding GO to
224 Our
primary objective was to determine whether interleukin-1
225 Our
primary objective was to determine whether previous radi
226 The
primary objective was to determine whether the cumulativ
227 Here, the
primary objective was to determine whether TSPO V(T) in
228 The
primary objective was to develop a coupled exposure-dose
229 The
primary objective was to directly compare diagnostic acc
230 The
primary objective was to establish a recommended phase I
231 The
primary objective was to establish the maximum tolerated
232 The
primary objective was to establish the safety and tolera
233 Our
primary objective was to estimate patient-level and tria
234 Our
primary objective was to estimate the excess mortality o
235 The
primary objective was to estimate the rate of pathologic
236 st severe form of systemic inflammation, the
primary objective was to evaluate chronic pain states an
237 The
primary objective was to evaluate median relapse-free su
238 The phase 2
primary objective was to evaluate overall response rate
239 The
primary objective was to evaluate overall survival at 1
240 The
primary objective was to evaluate the application of enz
241 The
primary objective was to evaluate the dose-response rela
242 Our
primary objective was to evaluate the effect of this cha
243 The
primary objective was to evaluate the efficacy of M72/AS
244 The
primary objective was to evaluate the efficacy of omaliz
245 The
primary objective was to evaluate the feasibility of sur
246 The
primary objective was to evaluate the impact of reduced
247 In the phase 2 portion, the
primary objective was to evaluate the overall response r
248 The
primary objective was to evaluate the safety and determi
249 The
primary objective was to evaluate the safety and tolerab
250 The
primary objective was to examine baseline clinical and D
251 Our
primary objective was to examine the HCV care continuum
252 The
primary objective was to explore the association between
253 The
primary objective was to identify the maximum tolerated
254 The
primary objective was to identify the maximum tolerated
255 Our
primary objective was to investigate a biomarker driven
256 The
primary objective was to investigate the effect of the S
257 MAIN OUTCOMES MEASURES: The
primary objective was to show noninferiority of ranibizu
258 iflozin dose groups pooled for analysis, the
primary objective was to show the noninferiority of ertu
259 The
primary objective was to show the noninferiority of plaz
260 Our
primary objective was to test for associations of the us
261 The
primary objective was to test the ability of a laparosco
262 The
primary objective was to test the hypothesis that the me
263 Our
primary objective was to test whether species would down
264 The
primary objective was to use antiretrovirals (raltegravi
265 The
primary objective was to validate the prognostic signifi
266 Safety (
primary objective)
was assessed via adverse events (AEs)
267 ffectiveness of the HRV vaccination program (
primary objective)
was measured by comparing the inciden
268 Primary objectives were assessments and comparisons of s
269 Primary objectives were evaluation of safety/tolerabilit
270 The
primary objectives were evaluation of the safety, tolera
271 The two
primary objectives were investigator-assessed progressio
272 The
primary objectives were safety and tolerability, and ant
273 The
primary objectives were safety and tolerability.
274 Primary objectives were safety and tolerability.
275 The
primary objectives were safety in patients who received
276 Primary objectives were safety, tolerability, and maximu
277 The
primary objectives were safety, tolerability, characteri
278 The
primary objectives were the HZ/su vaccine response rate
279 The
primary objectives were to assess feasibility and safety
280 Primary objectives were to assess safety in all particip
281 The
primary objectives were to assess the safety and evaluat
282 Primary objectives were to assess the safety and the max
283 The
primary objectives were to assess the safety of decitabi
284 Primary objectives were to assess the safety of rovalpit
285 Primary objectives were to assess the safety, toxicity,
286 Methods The
primary objectives were to assess tolerability, pharmaco
287 Primary objectives were to assess whether low sFlt-1:PlG
288 In this study, our
primary objectives were to clone the fathead minnow (FHM
289 Our
primary objectives were to determine overall survival, a
290 In the phase 1 dose-escalation portion, the
primary objectives were to determine the incidence of do
291 The
primary objectives were to determine the incidence of se
292 Phase 1
primary objectives were to determine the maximum tolerat
293 Primary objectives were to determine the maximum tolerat
294 Primary objectives were to determine the safety and tole
295 The
primary objectives were to establish individual readers'
296 The
primary objectives were to establish the maximum tolerat
297 The
primary objectives were to estimate and compare the sens
298 Primary objectives were to exclude inferiority of 10% or
299 Primary objectives were: confirmed prostate-specific ant
300 fied serotonin levels in brain synapses is a
primary objective when treating major depressive disorde